Proline Analog Ligands for Cannabinoid Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid receptor ligands lack specificity and efficacy in modulating CB1 and CB2 receptor functions for treating various conditions such as nausea, appetite regulation, pain, and glaucoma, with limited options for obesity and inflammatory diseases.
Innovation Solution
Development of Proline Analog Compounds that act as modulators of cannabinoid receptor functions, including agonists, antagonists, or inverse agonists, specifically targeting CB1 and CB2 receptors, with structures defined by specific chemical formulas to enhance therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cannabinoid receptor ligands are used, then they can bind to cannabinoid receptors, but they lack specificity and efficacy in modulating CB1 and CB2 receptor functions
Solution Approach 1:
The patent introduces specific local chemical modifications to the cannabinoid ligand structure, including the proline analog core with specific substituents at defined positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100). These localized structural changes enhance the ligand's ability to specifically interact with target cannabinoid receptors while maintaining selectivity between CB1 and CB2 subtypes, thereby resolving the contradiction between binding specificity and therapeutic efficacy.
Solution Approach 2:
The patent systematically varies multiple chemical parameters of the cannabinoid ligand structure, including substituent types, positions, and configurations, to optimize both receptor binding specificity and therapeutic efficacy. By adjusting parameters such as the nature of R groups (alkyl, aryl, heteroaryl, etc.), their positions on the proline analog core, and stereochemical configurations, the invention achieves ligands with enhanced specificity for desired receptor subtypes and improved therapeutic outcomes for various conditions.
2Adaptability or versatility
If current cannabinoid ligands are used to treat multiple conditions, then they have broad applicability, but they lack selective targeting capability for specific receptor subtypes
Solution Approach 1:
The patent divides the cannabinoid ligand structure into distinct functional segments: a proline analog core structure and various substituent groups (R1-R100) that can be independently optimized. This segmentation allows different parts of the molecule to contribute to different functions - the core provides basic cannabinoid receptor interaction while substituents fine-tune selectivity for CB1 versus CB2 receptors. This modular approach enables the development of ligands with tailored selectivity profiles for specific therapeutic indications while maintaining broad overall applicability.
Solution Approach 2:
The patent creates a universal proline analog scaffold that can serve multiple therapeutic purposes by simply changing the substituent pattern. The core structure is designed to interact with cannabinoid receptors in general, while the variable R groups provide condition-specific optimization. This multi-functional design allows a single compound class to address diverse conditions (pain, inflammation, nausea, appetite regulation, glaucoma, obesity, etc.) with appropriate receptor subtype selectivity, resolving the contradiction between versatility and selectivity.
Data Source
AI summary
The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.(Formula)